Last reviewed · How we verify
NCT06705465
Cross-sectorial Rehabilitation of Patients with Lung Cancer
NA trial testing video conference in Lung Cancer Non-Small Cell Cancer (NSCLC) in 130 participants. Currently enrolling.
1 July 2026
Quick facts
| Lead sponsor | Camilla Balle |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 130 |
| Start date | 7 October 2024 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- video conference
Conditions studied
- Lung Cancer Non-Small Cell Cancer (NSCLC) — all drugs for Lung Cancer Non-Small Cell Cancer (NSCLC) →
Sponsor
Camilla Balle
Who can join
18 and older, any sex, with Lung Cancer Non-Small Cell Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Four thousand seven hundred patients are diagnosed with lung cancer in Denmark every year. Even though cigarette smoking has declined for decades a decline in lung cancer incidence is still at least a decade away. Only 16% of these patients with lung cancer started in a municipal rehabilitation program. Aim: To investigate if the intervention "early contact conference" can facilitate acceptance of and participation in municipal rehabilitation in patients with lung cancer. Further, to investigate whether the rehabilitation improve the patients' physical ability and quality of life. Thirteen municipalities from Region Hovedstaden have agreed to participate in this cluster randomized controlled trial. The intervention will focus on creating early contact between the Department of Oncology and the municipalities. The conference call will be planned when the patient is at the hospital for the second systemic treatment and a written status will be sent to the GP after the conference video call so that hospital, municipality, and GP will all have the newest knowledge about the patient's general condition The intervention will be easy to implement in clinical practice afterwards if it is a success and the cost of the intervention is low.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06705465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Non-Small Cell Cancer (NSCLC)
Currently open trials in the same condition.
- NCT06810609 — Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06705465 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Camilla Balle
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06705465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing